de-DEen-US
Zum Inhalt springen
Ressourcen zur psychedelischen Forschung und Bewusstseinserweiterung (LSD Derivate)

Wissenschaftliche Forschung

Bedeutung und Potenzial von Psychedelika in der Wissenschaft

Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar II depression: open-label trial
Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar II depression: open-label trial

Aaronson, S.T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H.A., Suppes, T. (2024) JAMA Psychiatry , 81(6) , 555-562

Zusammenfassung

Open-label, nonrandomized trial of a single 25 mg dose of synthetic psilocybin with structured psychotherapy in adults with treatment-resistant bipolar II depression. Depressive symptoms improved at 3 and 12 weeks, with no significant increase in mania or suicidality, supporting further controlled studies in this population.

Schlüsselwörter

psilocybinbipolar IIdepressionopen-label trialpsychotherapytreatment-resistantsafetyclinical outcomes
Klinische Forschung
Artikel ansehen